Background: CCAAT/enhancer binding protein delta (C/EBPδ,CEBPD), a gene part of the highly conserved basicleucine zipper (b-ZIP) domain of transcriptional factors, is downregulated in 65% of high grade serous carcinomas of the ovary (HGSC). Overexpression of C/EBPδ in different tumours, such as glioblastoma and breast cancer either promotes tumour progression or inhibits growth and has low expression in normal tissue until activated by cytotoxic stressors. Methods: Higher overall expression of C/EBPδ in the luteal phase of the menstrual cycle prompted us to investigate the role of C/EBPδ in carcinogenesis. In vitro experiments were conducted in fallopian tube cell samples and cancer cell lines to investigate the role of C/EBPδ in proliferation, migration, and the epithelial to mesenchymal transition. Findings: Expression of C/EBPδ induced premature cellular arrest and decreased soft agar colony formation. Loss of C/EBPδ in epithelial cancer cell lines did not have significant effects on proliferation, yet overexpression demonstrated downregulation of growth, similar to normal fallopian tube cells. C/EBPδ promoted a partial mesenchymal to epithelial (MET) phenotype by upregulating E-cadherin and downregulating Vimentin and N-cadherin in FTE cells and increased migratory activity, which suggests a regulatory role in the epithelial-mesenchymal plasticity of these cells. Interpretation: Our findings suggest that C/EBPδ regulates the phenotype of normal fallopian tube cells by acting on downstream regulatory factors that are implicated in the development of ovarian serous carcinogenesis.
High Grade Serous Ovarian Cancer (HGSC) originates primarily from the fallopian tube epithelia. It is postulated that pre-malignant cells can migrate and implant onto the surface of the ovary. We previously reported that genes differentially expressed in the ovulatory phase can predispose the fallopian tube epithelia to transformation. Since ovulation is frequent, we hypothesize that C/EBPδ, a gene expressed in the luteal phase, can modulate the transformation of p53-mutated fallopian tube epithelial cells. Here, we show significantly decreased expression of C/EBPδ in HGSC compared to normal fallopian tube epithelia. We demonstrate that C/EBPδ, lost early during disease progression, is associated with a mesenchymal phenotype in normal fallopian tube epithelia. However, in a subset of HGSC, C/EBPδ expression is maintained. This pre-malignant subset of cells, that express C/EBPδ, promotes a mesenchymal to epithelial transition and promotes migration in the context of p53 mutation. While C/EBPδ over-expression induces cellular characteristics conducive to an EMT-MET switch, it also behaves as a tumor-suppressor, inhibiting cell cycle progression, indicative of its complex role in the pathogenesis of the disease.
Introduction: The most common and aggressive histotype of ovarian cancer is high-grade serous carcinoma (HGSC), which accounts for approximately 90% of deaths. Furthermore, the risk of developing HGSC is increased by having a mutation in the BRCA1 and BRCA2 gene. There is considerable evidence detailing the fallopian tube epithelia (FTE) as the site of origin of the disease, yet the ovarian surface epithelium (OSE) is still proposed as the site of origin by some. Currently, no studies have compared in vivo/xenografts models derived from FTE and OSE of BRCA mutation carriers. We suggest that in vivo/xenograft models can prove a useful tool for understanding the disease origins, meanwhile accounting for the genetic characteristics of the disease. Methodology: Immortalized and transformed cell lines, from both FTE and OSE, were derived from both BRCA1 and BRCA2 mutation carriers and non-carriers. In particular, 16 OSE cell lines were created--3 from BRCA1 carriers and noncarriers. Cell lines were transfected with hTERT and SV40, and either vectors overexpressing cMYC and hRASV12. 8 of these lines with cMYC or hRASV12 were injected into the mammary fat pad of 6-week-old female NSG mice (NOD.Cg-Prkdcscid). Similarly, 16 FTE lines were generated from 2-BRCA1 and 1 BRCA2 heterozygous mutation and 3 non-BRCA carriers overexpressing hTERT and SV40 with either cMYC or hRASV12. Results: To date, tumors have developed from mice injected with ovarian surface epithelial cells and fallopian tube epithelial cells at the mammary fat pad and the intraperitoneal cavity. FTE cells injected intraperitoneally produced ascites and displayed tumors lining the abdominal cavity and major organs. The parental immortal lines of 4 cases were karyotyped: FTE-37 and FTE-19 (controls); FTE-13 (BRCA2 mutant) and FTE-98 (BRCA1 mutant) cell lines demonstrated varying types of tetraploidy while the control (BRCA wild type) had fewer tetraploid chromosomes. Western blot analyses demonstrated that tumors express PAX8 and epithelial markers associated with HGSC. STR profiling using GenePrint 10 also revealed that injected FTE cells grown in vitro clustered with xenograft tumors of the same cell line, demonstrating that cell line and tumors retained the same characteristics during tumor development. It is hypothesized that SV40 alone is sufficient to stimulate genomic instability in the FTE cells. Several cell lines grown in culture with expression of hRASV12 demonstrated increased proliferation relative to normal control cells. Conclusions: Our results suggest that tumor development occurs at different rates in vivo and is dependent on multiple factors including genetic mutation, expression of oncogenes, and patient-derived characteristics. We demonstrated that cells grown in culture exhibit unstable chromosomal architecture characteristic of ovarian carcinomas, which is one of many potential factors that promotes neoplastic change in the tissue. Understanding how these factors act in promoting tumorigenesis will enable us to understand the molecular changes that occur in vivo prior to the development of ovarian serous carcinoma. Citation Format: Ramlogan Sowamber, Mauricio Medrano, Noor Salman, Zahra Maamir, Nick Chauvin, Mahmoud Bitar, Patricia Shaw, Sophia HL George. Differences in neoplastic transformation potential between OSE and FTE. [abstract]. In: Proceedings of the AACR Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment; Oct 1-4, 2017; Pittsburgh, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(15_Suppl):Abstract nr B12.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.